Lancet 19 May 2007 Vol 369

One week after the New England Journal published the two FUTURE studies, The Lancet publishes three trials of a quadrivalent vaccine against human papillomavirus types 6,11, 16 and 18. And it is indeed a case of back to the FUTURE – the vaccine shows protection against new high-grade vulval and vaginal lesions when given before, but not after, infection.

This report from the One Million Women Study
was much publicised when it appeared on-line: it confidently asserts that hormone replacement therapy is associated with a higher risk of ovarian cancer. This is expressed as “1,000 extra deaths since 1991